Healthcare

Share

Facebook Twitter Linkedin

Novo Nordisk A/S (NYSE:NVO)

139.16 USD

+1.640 1.193%

Last Updated at: 2024-08-30T20:23:00Z

Risk Disclaimer NVO chart by TradingView

Back to NYSE:NVO

Risk Disclaimer NVO chart by TradingView

Sponsored Reports

Loading...

Previous Close (in USD)	137.52
Change	+1.640 1.193%
52 W H/L (in USD)	105.690/63.878
EBITDA (in USD)	100106.002M
PE Ratio	41.58
Volume	2713470
Diluted Eps TTM	2.47

Total Assets (in USD)	241257M
Total Liabilities (in USD)	157771M
Revenue TTM (in USD)	214490.006M
Cash (in USD)	12653M
Market Cap (in USD)	457,910.977 M
Revenue Per Share TTM	47.733
Gross Profit TTM (in USD)	148506M

Summary

---

Income Statement

Balance Sheet

Change in Cash

Operating Cash

Dividend Paid

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Allé 1, Bagsvaerd, Denmark, 2880

45 44 44 88 88

https://www.novonordisk.com

Employees: 61412

Key Executives

Sr. No.	Name	Title	Year Born
1.	Mr. Lars Fruergaard Jorgensen	Pres, CEO & Member of Management Board	1966
2.	Mr. Karsten Munk Knudsen	Exec. VP, CFO & Member of the Management Board	1971
3.	Mr. Henrik Ehlers Wulff	Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board	1970
4.	Ms. Camilla Sylvest	Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board	1972
5.	Dr. Martin Holst Lange	Exec. VP, Head of Devel. & Member of the Management Board	1970
6.	Ms. Monique Carter	Exec. VP, Head of People & Organisation and Member of Management Board	1973
7.	Dr. Marcus Schindler Ph.D.	EVP, Head of Research & Early Devel., Chief Scientific Officer & Member of the Management Board	1966
8.	Mr. Maziar Mike Doustdar	Exec. VP, Head of International Operations & Member of the Management Board	1970
9.	Mr. Douglas J. Langa	Exec. VP, Head of North America Operations & Member of Management Board	1966
10.	Mr. Ludovic Helfgott	Exec. VP, Head of Rare Disease & Member of Management Board	1974

Peers

Sector: Healthcare

Industry: Biotechnology

Company	Change (USD)	Price (USD)	Trailing PE(x)	Forward PE(x)	Price Sales TTM(x)	Price to Book Value(x)	Enterprise Value to Revenue(x)	Enterprise Value to EBITDA(x)
NONOF Novo Nordisk A/S	-0.003 0.002%	138.64	41.060	31.250	2.078	33.111	2.113	4.700
VRTX Vertex Pharmaceuticals Inc	+2.540 0.515%	495.67	29.670	24.331	10.385	5.832	9.334	20.004
REGN Regeneron Pharmaceuticals Inc	+5.760 0.489%	1179.2	29.070	20.121	7.570	3.823	6.950	19.423
CSLLY CSL Ltd	-1.010 0.959%	104.75	42.450	26.954	7.054	5.797	7.851	26.506

• Income Statement
• Balance Sheet
• Cash Flow

Income Statement

(Currency in USD)

Breakdown	31-12-2022	31-12-2021	31-12-2020	31-12-2019	31-12-2018
Income Before Tax	69062M	59080M	53130M	48553M	47615M
Minority Interest	-	-	-	0M	0M
Net Income	55525M	47757M	42138M	38951M	38628M
Selling General Administrative	4467M	4050M	3958M	4007M	3916M
Gross Profit	148506M	117142M	106014M	101933M	94214M
Reconciled Depreciation	7362M	6025M	5753M	5661M	3925M
Ebit	74809M	58644M	54126M	52483M	47239M
Ebitda	82040M	67556M	60215M	57791M	51164M
Depreciation And Amortization	7231M	8912M	6089M	5308M	3925M
Operating Income	74809M	58644M	54126M	52483M	47248M
Other Operating Expenses	102145M	82156M	72820M	69538M	64583M
Interest Expense	378M	2451M	390M	220M	85M
Tax Provision	13537M	11323M	10992M	9602M	8987M
Interest Income	239M	558M	337M	3757M	439M
Net Interest Income	-320M	-180M	-203M	-436M	-106M
Income Tax Expense	13537M	11323M	10992M	9602M	8987M
Total Revenue	176954M	140800M	126946M	122021M	111831M
Total Operating Expenses	73697M	58498M	51888M	49450M	46966M
Cost Of Revenue	28448M	23658M	20932M	20088M	17617M
Total Other Income Expense Net	-5747M	436M	-996M	-3930M	473M
Net Income From Continuing Ops	55525M	47757M	42138M	38951M	38628M
Net Income Applicable To Common Shares	55525M	47757M	42138M	38951M	38628M

Balance Sheet

(Currency in USD)

Breakdown	31-12-2022	31-12-2021	31-12-2020	31-12-2019	31-12-2018
Total Assets	241257M	194508M	144922M	125612M	110769M
Intangible Assets	46324M	38825M	20657M	5835M	5145M
Other Current Assets	2727M	1690M	2332M	188M	204M
Total Liab	157771M	123762M	81597M	68019M	58930M
Total Stockholder Equity	83486M	70746M	63325M	57593M	51839M
Other Current Liab	103887M	21784M	18370M	15819M	41850M
Common Stock	456M	462M	470M	480M	490M
Capital Stock	456M	462M	470M	480M	490M
Retained Earnings	80587M	72004M	63774M	57817M	53406M
Good Will	5092M	4346M	-	0M	0M
Other Assets	13427M	8939M	6539M	4962M	2893M
Cash	12653M	10720M	12757M	15475M	15638M
Cash And Equivalents	-	-	-	-	-
Total Current Liabilities	120940M	99516M	70273M	58983M	54164M
Current Deferred Revenue	-	55178M	38727M	35332M	5043M
Net Debt	13131M	15925M	-2401M	-10992M	-15123M
Short Term Debt	1466M	13684M	7459M	1474M	515M
Short Long Term Debt	480M	12862M	6684M	659M	515M
Short Long Term Debt Total	25784M	26645M	10356M	4483M	515M
Other Stockholder Equity	-6M	-6M	-8M	-10M	-11M
Property Plant Equipment	66671M	55362M	50269M	50551M	41891M
Total Current Assets	108194M	85595M	65809M	62456M	59067M
Long Term Investments	1343M	1441M	1648M	1808M	1773M
Short Term Investments	10921M	6765M	-	0M	0M
Net Receivables	57505M	46799M	32184M	29152M	26889M
Long Term Debt	20775M	9654M	-	0M	0M
Inventory	24388M	19621M	18536M	17641M	16336M
Accounts Payable	15587M	8870M	5717M	6358M	6756M
Accumulated Other Comprehensive Income	2449M	-1714M	-911M	-694M	-2046M
Non Currrent Assets Other	206M	267M	674M	841M	51702M
Non Current Assets Total	133063M	108913M	79113M	63156M	51702M
Capital Lease Obligations	4529M	4129M	3672M	3824M	0M
Long Term Debt Total	24318M	12961M	2897M	3009M	0M

Cash Flow

(Currency in USD)

Breakdown	31-12-2022	31-12-2021	31-12-2020	31-12-2019	31-12-2018
Investments	-24918M	-5941M	-22436M	-11509M	-12080M
Total Cashflows From Investing Activities	-24918M	-31605M	-22436M	-11509M	-12080M
Total Cash From Financing Activities	-51797M	-25493M	-32244M	-35484M	-34521M
Net Income	55525M	47757M	42138M	38951M	38628M
Change In Cash	1934M	-1507M	-3185M	-218M	-1529M
Begin Period Cash Flow	10719M	12226M	15411M	15629M	17158M
End Period Cash Flow	12653M	10719M	12226M	15411M	15629M
Total Cash From Operating Activities	78887M	55000M	51951M	46782M	44616M
Depreciation	7362M	6025M	5753M	5661M	3925M
Other Cashflows From Investing Activities	-10165M	4M	18M	20M	19M
Dividends Paid	25303M	21517M	20121M	19409M	19048M
Change To Inventory	-4767M	-1085M	-895M	-1305M	-963M
Sale Purchase Of Stock	-24086M	-19447M	-16855M	-15334M	-15567M
Other Cashflows From Financing Activities	11215M	22160M	5682M	-11509M	94M
Capital Expenditures	14753M	7385M	22081M	11231M	12410M
Change In Working Capital	-5336M	-8656M	-4353M	-3388M	-3370M
Other Non Cash Items	6260M	-2489M	-3402M	-4407M	-3968M
Free Cash Flow	64134M	47615M	29870M	35551M	32206M

Funds

Sr. No.	Name	Purchased On	Shares
1.	Harbor Capital Appreciation Instl	11 months ago	5825550
2.	American Funds Washington Mutual A	11 months ago	3444654
3.	Capital Group Wash Mutual Invtrs Comp	11 months ago	3444654
4.	Bridge Builder Large Cap Growth	9 months ago	3001517
5.	Jennison Concentrated LC Growth Equity	11 months ago	2539206
6.	Vanguard US Growth Investor	11 months ago	2539206
7.	CREF Growth R1	10 months ago	2420031
8.	Loomis Sayles Growth Y	10 months ago	2365182
9.	Fidelity® Blue Chip Growth	10 months ago	2221894
10.	T. Rowe Price International Growth Eq	11 months ago	2101452
11.	T. Rowe Price International Stock	11 months ago	2101452
12.	Amana Growth Investor	9 months ago	2003200
13.	Harbor Capital Appreciation CIT 4	11 months ago	1968978
14.	Fidelity Growth Compy Commingled Pl O	10 months ago	1756348
15.	T. Rowe Price International Gr Eq Tr-D	11 months ago	1595066
16.	PGIM Jennison Growth A	9 months ago	1571136
17.	T. Rowe Price Health Sciences	11 months ago	1569835
18.	Polen Growth Institutional	11 months ago	1553073
19.	Fidelity® Growth Company	10 months ago	1340916
20.	DFA International Core Equity I	10 months ago	1177766

Institutions

Sr. No.	Name	Purchased On	Shares
1.	Jennison Associates LLC	11 months ago	23419405
2.	Renaissance Technologies Corp	11 months ago	16229476
3.	Fisher Asset Management, LLC	11 months ago	14748083
4.	Bank of America Corp	11 months ago	12781305
5.	FMR Inc	11 months ago	12077501
6.	Fayez Sarofim & Company	11 months ago	11603964
7.	Morgan Stanley - Brokerage Accounts	11 months ago	9215098
8.	Loomis, Sayles & Company LP	11 months ago	9097808
9.	Folketrygdfondet	11 months ago	8405442
10.	T. Rowe Price Associates, Inc.	11 months ago	8230915
11.	BlackRock Inc	11 months ago	8052306
12.	Polen Capital	11 months ago	7906255
13.	State Farm Mutual Automobile Ins Co	11 months ago	6755654
14.	State Street Corporation	11 months ago	6679660
15.	Everett Harris & Co	11 months ago	6539202
16.	WCM Investment Management	11 months ago	6528911
17.	Capital Research & Mgmt Co - Division 3	11 months ago	5817395
18.	Goldman Sachs Group Inc	11 months ago	4282003
19.	Capital World Investors	11 months ago	3966358
20.	Wells Fargo & Co	11 months ago	3676765

Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

• Top Gainer
• Top Loser